FUL

Over the past 12 months, H.B. Fuller's stock price declined by 14.2% as of October 6, 2026. In Q3 2026, the company reported adjusted EPS of $1.52, exceeding estimates, but revenue of $938 million missed forecasts, leading to a 4.1% stock decline the next day, though fiscal year 2026 guidance was maintained despite soft construction demand. In October 2026, H.B. Fuller announced pricing $850 million in new senior unsecured notes at 7.625% interest, maturing in 2034, to fund the acquisition of Advanced Medical Solutions Group plc (AMS), transaction fees, and general corporate purposes, with Fitch Ratings assigning a 'BB' rating. Effective April 1, 2026, H.B. Fuller implemented a minimum 10% global price increase across all product lines, with higher adjustments for certain technologies and regions, in response to broad-based constraints affecting availability and raw material costs. On October 7, 2026, Director R Jeffrey Bailly acquired 10,000 shares of the company's common stock for $500,000 at $50 per share, when the stock was near its 52-week low.